Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty.
De Luca G, van't Hof AW, Huber K, Gibson CM, Bellandi F, Arntz HR, Maioli M, Noc M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Dudek D; EGYPT cooperation. De Luca G, et al. Among authors: huber k. Am J Cardiol. 2013 Oct 15;112(8):1083-6. doi: 10.1016/j.amjcard.2013.05.053. Epub 2013 Aug 1. Am J Cardiol. 2013. PMID: 23910428 Clinical Trial.
Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction.
Hödl R, Huber K, Kraxner W, Nikfardjam M, Schumacher M, Fruhwald FM, Zorn G, Wonisch M, Klein W. Hödl R, et al. Among authors: huber k. Am J Cardiol. 2002 Mar 1;89(5):589-92. doi: 10.1016/s0002-9149(01)02300-1. Am J Cardiol. 2002. PMID: 11867046 No abstract available.
Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Atar D, Huber K, Rupprecht HJ, Kopecky SL, Schwitter J, Theek C, Brandl K, Henning R, Geudelin B. Atar D, et al. Among authors: huber k. Cardiology. 2007;108(2):117-23. doi: 10.1159/000095982. Epub 2006 Oct 2. Cardiology. 2007. PMID: 17019083 Clinical Trial.
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators; Bates E, Bode C, Costa M, Gibson CM, Granger C, Green C, Grimes K, Harrington R, Huber K, Kleiman N, Mochly-Rosen D, Roe M, Sadowski Z, Solomon S, Widimsky P. Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators, et al. Among authors: huber k. Circulation. 2008 Feb 19;117(7):886-96. doi: 10.1161/CIRCULATIONAHA.107.759167. Epub 2008 Feb 4. Circulation. 2008. PMID: 18250271 Clinical Trial.
Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation.
De Luca G, Michael Gibson C, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW. De Luca G, et al. Among authors: huber k. J Thromb Thrombolysis. 2009 Oct;28(3):288-98. doi: 10.1007/s11239-008-0296-9. Epub 2008 Nov 22. J Thromb Thrombolysis. 2009. PMID: 19030969
Gender-related outcome following percutaneous coronary intervention for ST-elevation myocardial infarction: data from the Austrian acute PCI registry.
Suessenbacher A, Doerler J, Alber H, Aichinger J, Altenberger J, Benzer W, Christ G, Globits S, Huber K, Karnik R, Norman G, Siostrzonek P, Zenker G, Pachinger O, Weidinger F. Suessenbacher A, et al. Among authors: huber k. EuroIntervention. 2008 Aug;4(2):271-6. doi: 10.4244/eijv4i2a47. EuroIntervention. 2008. PMID: 19110794
Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.
Atar D, Petzelbauer P, Schwitter J, Huber K, Rensing B, Kasprzak JD, Butter C, Grip L, Hansen PR, Süselbeck T, Clemmensen PM, Marin-Galiano M, Geudelin B, Buser PT; F.I.R.E. Investigators. Atar D, et al. Among authors: huber k. J Am Coll Cardiol. 2009 Feb 24;53(8):720-9. doi: 10.1016/j.jacc.2008.12.017. J Am Coll Cardiol. 2009. PMID: 19232907 Free article. Clinical Trial.
Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors.
De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW. De Luca G, et al. Among authors: huber k. Atherosclerosis. 2009 Nov;207(1):181-5. doi: 10.1016/j.atherosclerosis.2009.03.042. Epub 2009 Apr 5. Atherosclerosis. 2009. PMID: 19426981
2,099 results